Never Will I Ever Buy Preclinical Biotech Stocks. No Way!
It's "Never Will I Ever" week on Industry Focus, and we're explaining what we'll never invest in and why.
It's incredibly difficult to develop new, game-changing medicine. How difficult? Over 90% of drugs that enter phase 1 human trials end up in the dustbin, rather than pharmacy shelves. Clearly, investing in biotechnology stocks is a hit-or-miss proposition.
Looking for some examples of how risky it can be to buy early-stage biotech stocks? Look no further than Juno Therapeutics' (NASDAQ: JUNO) stumble last year. The company was forced to sideline its once-promising CAR-T medicine, JCAR015, because of unexpected patient deaths, and as a result, its share price is more than 50% below where it was in 2015.
Source: Fool.com
